Merck & Co., Inc（MRK）の決算・業績分析
Merck & Co., Incの2025年有価証券報告書をAI分析。売上高$65.0B(+1.3%)。Health Care。
目次
Merck & Co., Incの2025年度 業績サマリー
Merck & Co., Inc（証券コード: MRK）の2025年度決算・業績分析。売上高は$65.0B（前年比+1.3%）。純利益は$18.3B（前年比+6.6%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
Merck & Co., Incの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Merck achieved a 21.7% YoY revenue increase to $59.3B (XBRL), driven by strong performance in key products like Keytruda and Gardasil.
- Net income rose 11.3% YoY to $14.5B (XBRL), supported by robust operating margins of 30.8% and a net margin of 24.5%.
- Return on equity (ROE) reached 38.6% (XBRL), reflecting efficient capital utilization despite a net debt-to-EBITDA ratio of 1.3x (XBRL).
Merck & Co., Incの売上高変化の要因
- •FY2024 revenue of $59.3B (XBRL) reflects a 21.7% YoY increase, with historical growth of +7.3% CAGR over five years (XBRL). Key drivers include strong sales of Keytruda and Gardasil, though net income CAGR over five years declined sharply at -43.3% (XBRL). The company's revenue growth is tempered by challenges such as declining Gardasil sales in China (10-K). Segment-specific revenue details are not disclosed in the provided data (XBRL).
Merck & Co., Incの営業利益変化の要因
- •Merck reported operating income of $18.3B (XBRL) and EBITDA of $20.1B (33.9% margin). Net income of $14.5B (24.5% margin) rose 11.3% YoY (XBRL). Operating margins improved to 30.8%, though historical data lacks prior-year comparisons for operating income. The company's profitability is supported by high R&D investment ($13.5B) and efficient cost management (10-K).
Merck & Co., Incの事業リスクと対応
Patent dependency: Loss of patent rights could severely impact revenue (10-K).
Market exclusivity loss: Declining sales from products losing exclusivity pose significant revenue risks (10-K).
Key product reliance: Concentration on high-profit products exposes Merck to market volatility (10-K).
R&D failure: Inability to develop or acquire new products risks long-term growth (10-K).
Competition: Pressure from generics, biosimilars, and rivals threatens market share and pricing (10-K).
Geopolitical risks: Regulatory changes and healthcare politicization may affect operations (10-K).
Merck & Co., Incの今後の見通し・業績予想
Merck & Co., Incの事業内容
Merck is a global healthcare company generating revenue through the sale of prescription medicines, vaccines, and animal health products (10-K). Its Pharmaceutical segment includes high-margin products like Keytruda (immunotherapy) and Gardasil (HPV vaccine), while the Animal Health segment provides veterinary pharmaceuticals and vaccines (10-K). Merck's competitive advantages include a $13.5B R&D investment (XBRL) and a diversified portfolio spanning human and animal health. However, the company faces risks related to patent expiration, market exclusivity loss, and reliance on key products (10-K).
Merck & Co., IncのAI業績分析レポート（2024年度）
Merck & Co., Inc. (MRK) FY2024 Annual Report Analysis
Highlights
Business Overview
Merck operates in the global healthcare sector, generating revenue through prescription medicines, vaccines, and animal health products (10-K). Its Pharmaceutical segment includes blockbuster drugs like Keytruda (immunotherapy) and Gardasil (HPV vaccine), while the Animal Health segment serves livestock and companion animals (10-K). Merck's competitive advantages include a $13.5B R&D investment (XBRL) and a diversified portfolio. However, risks include patent expiration, market exclusivity loss, and reliance on key products (10-K).
Revenue Analysis
FY2024 revenue of $59.3B (XBRL) reflects a 21.7% YoY increase, with historical growth of +7.3% CAGR over five years (XBRL). Key drivers include strong sales of Keytruda and Gardasil, though net income CAGR over five years declined sharply at -43.3% (XBRL). The company's revenue growth is tempered by challenges such as declining Gardasil sales in China (10-K). Segment-specific revenue details are not disclosed in the provided data (XBRL).
Profitability Analysis
Merck reported operating income of $18.3B (XBRL) and EBITDA of $20.1B (33.9% margin). Net income of $14.5B (24.5% margin) rose 11.3% YoY (XBRL). Operating margins improved to 30.8%, though historical data lacks prior-year comparisons for operating income. The company's profitability is supported by high R&D investment ($13.5B) and efficient cost management (10-K).
Balance Sheet Analysis
Total assets stood at $106.7B (XBRL), with total equity of $37.6B (XBRL). The equity ratio of 35.2% (XBRL) and current ratio of 1.25x indicate moderate leverage and liquidity. Long-term debt of $33.7B (XBRL) and net debt of $26.8B (1.3x EBITDA) suggest manageable debt levels despite significant capital expenditures.
Cash Flow Analysis
Operating cash flow reached $19.1B (XBRL), with free cash flow (FCF) of $14.7B after $4.4B in capital expenditures (XBRL). Dividends paid totaled $7.0B (XBRL), while no share repurchases were conducted. The company's strong cash position ($6.8B) supports its dividend policy and debt management.
Working Capital Analysis
Merck's cash conversion cycle (CCC) was 115 days (XBRL), with receivables days at 64, inventory days at 133, and payables days at 82. These metrics suggest room for improvement in inventory management and supplier negotiation.
Risks
Outlook
Management guidance and forward-looking trends are not explicitly detailed in the provided 10-K or XBRL data.
Health Careの企業一覧
Merck & Co., Incと同じ「Health Care」セクターの企業